Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition
Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain une...
| Glavni autori: | , , , , |
|---|---|
| Daljnji autori: | |
| Format: | Članak |
| Jezik: | English |
| Izdano: |
Springer US
2018
|
| Online pristup: | http://hdl.handle.net/1721.1/117218 https://orcid.org/0000-0003-1224-8153 https://orcid.org/0000-0001-6284-2711 https://orcid.org/0000-0002-0050-989X |
| Sažetak: | Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain unexplained by genomic properties. Emerging evidence shows that receptor tyrosine kinase (RTK) reprogramming is a major alternative process causing targeted drug resistance, separate from genetic alterations. Hence, the contributions of mechanisms leading to this process need to be more rigorously assessed. |
|---|